Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027508 | 0.88 | PIK3CD (0.53) | HSD17B10ACEPOLBCYP2D6CYP2C9 | |
| SCHEMBL4787017 | 0.82 | TSHR (0.48) | KDM4EPIK3CDNAAAMAPK1 | |
| SCHEMBL15125171 | 0.82 | PIK3CD (0.42) | KDM4EKMT2APIK3CDNAAAMAPK1 | |
| SCHEMBL11983582 | 0.82 | PIK3CD (0.42) | KDM4EPIK3CDNAAAMAPK1ALDH1A1 | |
| SCHEMBL7769442 | 0.82 | KDM4E (0.39) | KDM4EKMT2APIK3CDNAAAMAPK1 | |
| SCHEMBL17302394 | 0.81 | HSD17B10 (0.45) | HSD17B10KDM4EPOLBCYP2D6CYP2C9 | |
| SCHEMBL5025746 | 0.80 | CYP2D6 (0.41) | HSD17B10ACEKDM4EPOLBCYP2D6 | |
| SCHEMBL17662299 | 0.80 | KDM4E (0.45) | KDM4EPOLBKMT2APIK3CDNAAA | |
| SCHEMBL13096630 | 0.79 | NAAA (0.42) | KDM4EPIK3CDNAAAMAPK1ALDH1A1 | |
| SCHEMBL2825590 | 0.77 | ALDH1A1 (0.41) | KDM4EPOLBKMT2APIK3CDNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113462825-A | Novel environment-friendly tanning process | 河北耿氏同盈裘革制品股份有限公司 | 2021-10-01 | — | — | CN | claimed |
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-112979631-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| EP-1539687-A1 | SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS | Pfizer Limited (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040092498-A1 | Substituted glycine derivatives for use as medicaments | BLAKEMORE DAVID (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016583-A1 | SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| EP-0362902-A2 | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-04-11 | — | — | EP | disclosed |
| US-4775752-A | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0209352-A2 | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092498-A1 | Substituted glycine derivatives for use as medicaments | GLRA1, GRM1, GPR6 | HSD17B10 1813/4885ACE 2856/4885KDM4E 3580/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | HSD17B10 2509/4885ACE 514/4885KDM4E 4030/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | HSD17B10 2344/4885ACE 1975/4885KDM4E 1561/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | HSD17B10 2507/4885ACE 1706/4885KDM4E 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.